Trial Profile
A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatment of patients with seasonal allergic rhinoconjunctivitis due to grass pollen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2019
Price :
$35
*
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Allergy Therapeutics
- 25 Feb 2019 Results assessing a strong dose-response Using a Conjunctival Provocation Test, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 25 Feb 2019 Results assessing Strong Dose-response On Immunoglobulin Makers, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 25 Jun 2018 According to an Allergy Therapeutics media release, company announces the publication of positive data in the journal Immunotherapy.